Results 71 to 80 of about 6,658 (202)

Olaparib‐associated cutaneous vasculitis in a patient with breast cancer

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca, Teresa Puértolas, Adrián Diago, María Carmen Gómez‐Mateo   +3 more
wiley   +1 more source

Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Graphical Highlights Spatiotemporal immune heterogeneity shapes distinct and evolving immune ecosystems in ovarian cancer. Multimodal biomarkers enable biologically informed patient stratification beyond static single‐marker approaches. Precision immunotherapy should match dominant immune barriers across lesions and treatment stages.
Xinfeng Yang, Yida Wang, Haiyue You, Jingyi Gao, Yangkun Feng, Feng Zhang, Yan Zhang, Bing Zhang, Shaojie Zhao, Yanfang Gu   +9 more
wiley   +1 more source

Heterogeneity of rucaparib activity in arteries isolated from patients having undergone nephrectomy.

, 2015
Panel A; concentration-response curves that were generated. Tissues were constricted using 10 μM PE, before being treated with PE and the relevant concentration of rucaparib.
Tracy Robson (282407), Hiu-Fung Yuen (276126), Declan O’Rourke (692863), Martin G. O’Rourke (692861), Cian M. McCrudden (276127), Chris Hagan (692868), Joe M. O’Sullivan (275899), David G. Hirst (282406), Huw D. Thomas (114714), Nicola J. Curtin (351064), Kim E. Cherry (692862), Patrick Keane (692866), Chris Shaw (285026), Kaye J. Williams (692869), Muhammad Babur (692864), Brian A. Telfer (692865), Thiagarajan Nambirajan (692867)   +16 more
core   +1 more source

Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age

International Journal of Gynecology &Obstetrics, Volume 174, Issue 3, Page 1151-1171, September 2026.
Abstract Recent advances in cancer screening, diagnosis, and treatment have greatly improved survival rates among women with gynecologic cancers. More survivors now live long enough to experience treatment‐related menopause. Vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long‐term risks from estrogen ...
Agnaldo Lopes da Silva‐Filho, Suvarna Khadilkar, Hema Divakar, Chiara Benedetto, Andrea R. Genazzani, Diana Ramos, Elizabete Argale, Enrique Herrera, Martha Hickey   +8 more
wiley   +1 more source

Rucaparib may act at multiple P2 receptor subtypes.

, 2015
Panels A and B; blockade of specific P2 receptor subtypes P2X4, P2X7 and P2Y1 in tail artery (A) and aorta (B) models failed to categorically identify the receptor subtype at which rucaparib elicits its dilatory effect.
Tracy Robson (282407), Hiu-Fung Yuen (276126), Declan O’Rourke (692863), Martin G. O’Rourke (692861), Cian M. McCrudden (276127), Chris Hagan (692868), Joe M. O’Sullivan (275899), David G. Hirst (282406), Huw D. Thomas (114714), Nicola J. Curtin (351064), Kim E. Cherry (692862), Patrick Keane (692866), Chris Shaw (285026), Kaye J. Williams (692869), Muhammad Babur (692864), Brian A. Telfer (692865), Thiagarajan Nambirajan (692867)   +16 more
core   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Synthesis and Characterization of Transferrin Receptor-Targeted Peptide Combination SN-38 and Rucaparib Conjugate for the Treatment of Glioblastoma

Pharmaceutics
Background/Objectives: Glioblastoma represents a particularly aggressive and fatal type of brain tumor. Peptide-drug conjugates, which offer the promise of traversing the blood-brain barrier to selectively accumulate in tumor tissues and precisely target
Perpetue Bataille Backer, Simeon Kolawole Adesina   +1 more
doaj   +1 more source

Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer

Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas   +3 more
wiley   +1 more source

Understanding Postmarketing Requirements and Commitments for CYP3A‐Mediated Drug–Drug Interactions: An Analysis of FDA‐Approved Drugs From 2015 to 2024

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Jingjing Yu, Ichiko Petrie, Sophie Argon, Katie Owens, Isabelle Ragueneau‐Majlessi   +4 more
wiley   +1 more source

Emerging treatment options for ovarian cancer: focus on rucaparib

, 2017
Lavanya Mariappan,1 Xue Yan Jiang,1 Josie Jackson,2 Yvette Drew2 1Northern Centre for Cancer Care, Freeman Hospital, 2Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK Abstract: Poly(ADP-ribose) polymerase (PARP ...
Drew Y, Mariappan L, Jiang XY, Jackson J
core